"How long have SGLT2 inhibitors been used as SoC for CVD or diabetic CVD patients?"

I don't know for sure whether it is correct to call SGLT2 inhibitors or GLP1-R agonists standard of care yet. So perhaps my title to the thread is misleading. Maybe baseline medications is a better description. CVOT trials showing MACE reduction for SGLT2 inhibitors and GLP1-R agonists only started reading out in the past few years. These agents were approved prior to the CVOT results for glucose control, but only recently proved their MACE reduction and were only recently approved for marketing for CVD reduction. As with any new therapy, use increases over time. Maybe someone with clinical experience can chime in. There are a lot of new drug tools in the doctor's toolbox so there may be a lot of subjective opinions and some confusion amongst some docs leading to different prescribing practices.

BearDownAZ